VSVanessa Shih

Vanessa Shih

*This is an algorithmically generated author record based on publicly available information.

Vanessa Shih has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and Economic Burden of Glaucoma by Disease Severity

    by Vanessa Shih, Mousam Parekh, Jasjit K. Multani, Catherine B. McGuiness, Chi-Chang Chen, Joanna H. Campbell, Eydie Miller-Ellis, Mildred M.G. Olivier


  • Open Access

    Management and Outcomes for Neovascular Age-Related Macular Degeneration

    by Szilárd Kiss, Joanna Campbell, Arghavan Almony, Vanessa Shih, Michael Serbin, Andrew LaPrise, Charles C. Wykoff


  • Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids

    by Vanessa Shih, Erika Banks, Nicole G. Bonine, Amanda Harrington, Dana Stafkey-Mailey, Binglin Yue, Jiatao Michael Ye, Rupali M. Fuldeore, Patrick Gillard

    Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18–64 years with ≥1 inpatient or outpatient medical claim with an initial UF diagnosis (index date) from 1 January 2010 to 31 December 2014 were included. Healthcare resource utilization (HCRU) data including pharmacy, outpatient and inpatient hospital claims were collected for 1 year pre-index and ≤5 years post-index. All-cause costs (adjusted to 2017 $US) were compared between cases and controls using multivariable regression models. Results: Analysis included 205,098 (Commercial) and 24,755 (Medicaid) case–control pairs. HCRU and total all-cause healthcare costs were higher for cases versus controls during the pre-index year and all years post-index. Total unadjusted mean all-cause costs were $1197 higher (p < .0001; Commercial) and $2813 higher (standardized difference 0.08; Medicaid) for cases during the pre-index year. Total adjusted mean all-cause costs in the first year post-index were $14,917 for cases versus $5717 for controls in the Commercial population, and $20,244 versus $10,544, respectively, in the Medicaid population. In Years 2–5 post-index, incremental mean adjusted total costs decreased, but remained significantly higher for cases versus controls at all time points in both populations (all p < .05). Conclusions: Costs were higher for women with UF compared to women without UF during the pre-index year and over 5 years post-index; differences were greatest in the first year post-index.